Advanced search
1 file | 836.70 KB Add to list

Healthcare use and healthcare costs for patients with advanced cancer : the international ACTION cluster-randomised trial on advance care planning

(2023) PALLIATIVE MEDICINE. 37(5). p.707-718
Author
Organization
Abstract
Background: Advance care planning supports patients to reflect on and discuss preferences for future treatment and care. Studies of the impact of advance care planning on healthcare use and healthcare costs are scarce. Aim: To determine the impact on healthcare use and costs of an advance care planning intervention across six European countries. Design: Cluster-randomised trial, registered as ISRCTN63110516, of advance care planning conversations supported by certified facilitators. Setting/participants: Patients with advanced lung or colorectal cancer from 23 hospitals in Belgium, Denmark, Italy, the Netherlands, Slovenia and the UK. Data on healthcare use were collected from hospital medical files during 12 months after inclusion. Results: Patients with a good performance status were underrepresented in the intervention group (p< 0.001). Intervention and control patients spent on average 9 versus 8 days in hospital (p = 0.07) and the average number of X-rays was 1.9 in both groups. Fewer intervention than control patients received systemic cancer treatment; 79% versus 89%, respectively (p< 0.001). Total average costs of hospital care during 12 months follow-up were euro32,700 for intervention versus euro40,700 for control patients (p = 0.04 with bootstrap analyses). Multivariable multilevel models showed that lower average costs of care in the intervention group related to differences between study groups in country, religion and WHO-status. No effect of the intervention on differences in costs between study groups was observed (p = 0.3). Conclusions: Lower care costs as observed in the intervention group were mainly related to patients' characteristics. A definite impact of the intervention itself could not be established.
Keywords
Anesthesiology and Pain Medicine, General Medicine, randomised controlled trial, delivery of health care, cancer, health care costs, Advance care planning

Downloads

  • Publisher version.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 836.70 KB

Citation

Please use this url to cite or link to this publication:

MLA
Korfage, Ida J., et al. “Healthcare Use and Healthcare Costs for Patients with Advanced Cancer : The International ACTION Cluster-Randomised Trial on Advance Care Planning.” PALLIATIVE MEDICINE, vol. 37, no. 5, 2023, pp. 707–18, doi:10.1177/02692163221142950.
APA
Korfage, I. J., Polinder, S., Preston, N., van Delden, J. J., Geraerds, S. (A)JLM, Dunleavy, L., … Rietjens, J. A. (2023). Healthcare use and healthcare costs for patients with advanced cancer : the international ACTION cluster-randomised trial on advance care planning. PALLIATIVE MEDICINE, 37(5), 707–718. https://doi.org/10.1177/02692163221142950
Chicago author-date
Korfage, Ida J, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, Sandra (A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, et al. 2023. “Healthcare Use and Healthcare Costs for Patients with Advanced Cancer : The International ACTION Cluster-Randomised Trial on Advance Care Planning.” PALLIATIVE MEDICINE 37 (5): 707–18. https://doi.org/10.1177/02692163221142950.
Chicago author-date (all authors)
Korfage, Ida J, Suzanne Polinder, Nancy Preston, Johannes JM van Delden, Sandra (A)JLM Geraerds, Lesley Dunleavy, Kristof Faes, Guido Miccinesi, Giulia Carreras, Caroline Moeller Arnfeldt, Marijke C Kars, Giuseppe Lippi, Urska Lunder, Ceu Mateus, Kristian Pollock, Luc Deliens, Mogens Groenvold, Agnes van der Heide, and Judith AC Rietjens. 2023. “Healthcare Use and Healthcare Costs for Patients with Advanced Cancer : The International ACTION Cluster-Randomised Trial on Advance Care Planning.” PALLIATIVE MEDICINE 37 (5): 707–718. doi:10.1177/02692163221142950.
Vancouver
1.
Korfage IJ, Polinder S, Preston N, van Delden JJ, Geraerds S (A)JLM, Dunleavy L, et al. Healthcare use and healthcare costs for patients with advanced cancer : the international ACTION cluster-randomised trial on advance care planning. PALLIATIVE MEDICINE. 2023;37(5):707–18.
IEEE
[1]
I. J. Korfage et al., “Healthcare use and healthcare costs for patients with advanced cancer : the international ACTION cluster-randomised trial on advance care planning,” PALLIATIVE MEDICINE, vol. 37, no. 5, pp. 707–718, 2023.
@article{01GPJRN041PGHJJ7MAH214P34F,
  abstract     = {{Background: Advance care planning supports patients to reflect on and discuss preferences for future treatment and care. Studies of the impact of advance care planning on healthcare use and healthcare costs are scarce. Aim: To determine the impact on healthcare use and costs of an advance care planning intervention across six European countries. Design: Cluster-randomised trial, registered as ISRCTN63110516, of advance care planning conversations supported by certified facilitators. Setting/participants: Patients with advanced lung or colorectal cancer from 23 hospitals in Belgium, Denmark, Italy, the Netherlands, Slovenia and the UK. Data on healthcare use were collected from hospital medical files during 12 months after inclusion. Results: Patients with a good performance status were underrepresented in the intervention group (p< 0.001). Intervention and control patients spent on average 9 versus 8 days in hospital (p = 0.07) and the average number of X-rays was 1.9 in both groups. Fewer intervention than control patients received systemic cancer treatment; 79% versus 89%, respectively (p< 0.001). Total average costs of hospital care during 12 months follow-up were euro32,700 for intervention versus euro40,700 for control patients (p = 0.04 with bootstrap analyses). Multivariable multilevel models showed that lower average costs of care in the intervention group related to differences between study groups in country, religion and WHO-status. No effect of the intervention on differences in costs between study groups was observed (p = 0.3). Conclusions: Lower care costs as observed in the intervention group were mainly related to patients' characteristics. A definite impact of the intervention itself could not be established.}},
  author       = {{Korfage, Ida J and Polinder, Suzanne and Preston, Nancy and van Delden, Johannes JM and Geraerds, Sandra (A)JLM and Dunleavy, Lesley and Faes, Kristof and Miccinesi, Guido and Carreras, Giulia and Moeller Arnfeldt, Caroline and Kars, Marijke C and Lippi, Giuseppe and Lunder, Urska and Mateus, Ceu and Pollock, Kristian and Deliens, Luc and Groenvold, Mogens and van der Heide, Agnes and Rietjens, Judith AC}},
  issn         = {{0269-2163}},
  journal      = {{PALLIATIVE MEDICINE}},
  keywords     = {{Anesthesiology and Pain Medicine,General Medicine,randomised controlled trial,delivery of health care,cancer,health care costs,Advance care planning}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{707--718}},
  title        = {{Healthcare use and healthcare costs for patients with advanced cancer : the international ACTION cluster-randomised trial on advance care planning}},
  url          = {{http://doi.org/10.1177/02692163221142950}},
  volume       = {{37}},
  year         = {{2023}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: